[HTML][HTML] Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo …
SH Khoo, R FitzGerald, G Saunders… - The Lancet Infectious …, 2023 - thelancet.com
Background The antiviral drug molnupiravir was licensed for treating at-risk patients with
COVID-19 on the basis of data from unvaccinated adults. We aimed to evaluate the safety …
COVID-19 on the basis of data from unvaccinated adults. We aimed to evaluate the safety …
[HTML][HTML] Molnupiravir: first approval
YY Syed - Drugs, 2022 - Springer
Molnupiravir (Lagevrio®) is an orally-administered antiviral prodrug that inhibits replication
of RNA viruses through viral error induction. It is being developed by Merck and Ridgeback …
of RNA viruses through viral error induction. It is being developed by Merck and Ridgeback …
[HTML][HTML] The effect of molnupiravir on post-acute outcome of COVID-19 survivors
We read with great interest the review article by Gary et al., in which they raised several
concerns about the use of molnupiravir in the treatment of patients with COVID-19. 1 At the …
concerns about the use of molnupiravir in the treatment of patients with COVID-19. 1 At the …
[HTML][HTML] Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance
R Flisiak, D Zarębska-Michaluk, M Rogalska… - Pharmacological …, 2022 - Springer
Background The real-world effectiveness of molnupiravir (MOL) during the dominance of
Omicron SARS-CoV-2 lineage is urgently needed since the available data relate to the …
Omicron SARS-CoV-2 lineage is urgently needed since the available data relate to the …
[HTML][HTML] Real-world clinical outcomes of molnupiravir for the treatment of mild to moderate COVID-19 in adult patients during the dominance of the Omicron variant: a …
C Huang, TL Lu, L Lin - Antibiotics, 2023 - mdpi.com
Introduction: The therapeutic impact of molnupiravir in the Omicron variant phase is
unknown. The goal of the current meta-analysis was to compare the real-world clinical …
unknown. The goal of the current meta-analysis was to compare the real-world clinical …
A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus
There is an urgent need for an effective, oral, direct-acting therapeutic to block transmission
of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and prevent progression …
of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and prevent progression …
Molnupiravir: is it time to move in or move out?
NE Castillo Almeida, AC Kalil - NEJM evidence, 2022 - evidence.nejm.org
Molnupiravir: Is It Time to Move In or Move Out? With more than 250 million diagnosed
cases and 5 million deaths, Covid-19 is our epoch-defining pandemic—and it is still …
cases and 5 million deaths, Covid-19 is our epoch-defining pandemic—and it is still …
Molnupiravir and risk of post-acute sequelae of covid-19: cohort study
Objective To examine whether treatment with the antiviral agent molnupiravir during the first
five days of SARS-CoV-2 infection is associated with reduced risk of post-acute adverse …
five days of SARS-CoV-2 infection is associated with reduced risk of post-acute adverse …
[HTML][HTML] Efficacy and safety of molnupiravir for COVID-19 patients
The Coronavirus Disease 2019 (COVID-19) continues to be a major source of morbidity and
mortality across the globe. Current medical therapy against COVID-19 includes drugs that …
mortality across the globe. Current medical therapy against COVID-19 includes drugs that …
[HTML][HTML] Molnupiravir and nirmatrelvir/ritonavir: tolerability, safety, and adherence in a retrospective cohort study
Background. Molnupiravir (MOL) and nirmatrelvir/ritonavir (NIR) were recently approved for
the early treatment of COVID-19, but real-life data on tolerability, safety, and adverse events …
the early treatment of COVID-19, but real-life data on tolerability, safety, and adverse events …